Bevacizumab for recurrent ependymoma Academic Article uri icon

Overview

MeSH Major

  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal
  • Brain Neoplasms
  • Ependymoma
  • Neoplasm Recurrence, Local

abstract

  • The radiographic response rate to bevacizumab-containing regimens is high. A prospective study is warranted.

publication date

  • November 2009

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC2788805

Digital Object Identifier (DOI)

  • 10.1212/WNL.0b013e3181c1df34

PubMed ID

  • 19917990

Additional Document Info

start page

  • 1677

end page

  • 80

volume

  • 73

number

  • 20